Leadership & Governance
Management Team
Atul Deshpande
CHIEF EXECUTIVE OFFICER
Prior to joining IMMEDIATE Therapeutics, Atul was the Chief Strategy Officer at Peptilogics. Atul was primarily responsible for building the company’s short- and long-term strategy and portfolio along with a robust execution plan. He was also responsible for business development and fundraising activities. He, along with the team closed a round of $78M in 2025 for the company.
Prior to Peptilogics, Atul was the Chief Strategy Officer and Head, US Operations for Harbour Biomed. He was primarily responsible for the company’s portfolio build and fundraise. In addition, he was also accountable for the HBM’s operations in both the US and EU to maintain HBM’s footprint across these 2 very important markets, along with managing key alliances in these regions. In 2020, he contributed to raising 2 VC funding rounds and taking the company public in the HK stock exchange raising a total of $400M.
Before HBM, Atul served as the Global Operations Head for the Dupixent Franchise with Sanofi. He led the operations, including marketing, market access, supply chain, to launch Dupixent in 52 markets across the world for Atopic Dermatitis and in major markets for Asthma. Prior to this, he led the operations for Sanofi’s Immunology R&D portfolio and was also responsible for new product planning and in-licensing evaluations. He spent 3 years in China as the Head of Asia Pacific R&D strategy to bring the global portfolio to China with minimal drug lag. Before Sanofi, Atul worked as a management consultant for 9 years on projects across the value chain of pharma.
Atul holds a PhD in Neuroscience from University of California, Irvine, and an MBA from Cranfield University, UK.
Harry Selker
FOUNDER, CHIEF SCIENTIFIC OFFICER
Dr. Harry Selker is Dean of Tufts Clinical and Translational Science Institute at Tufts University and Executive Director of the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center. He is known for research in emergency cardiac care and the development of “clinical predictive instruments,” mathematical models built into electrocardiographs as decision aids. These enabled very early treatment of patients with acute coronary syndromes in ambulances with intravenous glucose-insulin-potassium (GIK), which in the IMMEDIATE Trial, dramatically reduced cardiac arrest, mortality, and heart attack size. His work has led to multiple patents, over 200 publications, over $200 million in research funding, and honors for his research and leadership
Dr. Selker has been president of five national professional and scientific organizations and an advisor to Congress, government, and organizations. He attended Reed College (BA), Brown University (MD), and UCLA (MSPH).
James Udelson
CHIEF MEDICAL OFFICER
Dr. James Udelson is Chief of the Division of Cardiology at Tufts Medical Center and Professor of Medicine and Radiology at Tufts University School of Medicine.
He was an Associate Editor for Circulation from 2004 – 2016 and founding Editor-in-Chief for Circulation: Heart Failure. He is a chapter author for Braunwald’s Heart Disease textbook.
Dr. Udelson served on the Board of Trustees of the ACC, on the Executive Council of the Heart Failure Society of America, and was President of the American Society of Nuclear Cardiology.
He was a member of the FDA Medical Imaging Drugs Advisory Panel and an ad hoc member of the FDA’s Cardiovascular and Renal Drugs Advisory Panel. He has been the recipient of several NIH grants for studies of the use of cardiac imaging to favorably influence clinical decision making. He has designed, directed and/or participated in numerous clinical trials on heart failure and cardiac imaging.
Bradley Newman
Global Head of Manufacturing & Supply Chain
Bradley Newman is an experienced biopharmaceutical operations leader with more than 30 years’ experience in sterile products commercialization, manufacturing, supply chain strategy, and late-stage commercial development.
Prior to IMMEDIATE Therapeutics, Mr. Newman served as Senior Director, Commercial Operations at Baxter BioPharma Solutions (now Simtra), a leading sterile CDMO, where he drove strategic partnerships, contract development, and commercialization efforts on behalf of large biopharmaceutical clients. In this role, he managed cross-functional teams to ensure seamless integration of manufacturing capabilities with client needs, supporting scale-up and market entry for innovative IV and injectable therapies. Earlier in his career, he held various insulin marketing and new product commercialization roles with Eli Lilly and Company.
At IMMEDIATE Therapeutics, Mr. Newman oversees global manufacturing and supply chain strategy for IMT-358, including CMC execution, external manufacturing partnerships, and preparation for commercial-scale IV container production. His role is central to aligning development timelines with regulatory expectations ensuring manufacturing and supply readiness in support of pivotal Phase 3 development and future commercialization.
Mr. Newman holds a BSEE from Rose-Hulman Institute of Technology and an MBA from Butler University.
Chia-Wen Lee
Global Head of Market Access
Dr. Chia-Wen Lee leads U.S. and global market access strategy for IMT-358, translating clinical evidence into payer-credible value propositions and scalable reimbursement pathways across major markets.
She oversees end-to-end access planning — from early payer and HTA engagement through evidence generation strategy, pricing architecture, coverage and payment design, institutional key account strategy, and launch readiness — aligning Clinical Development, Medical, HEOR/RWE, Regulatory, and Commercial teams around a unified value narrative.
Trained as a PhD epidemiologist, Dr. Lee brings deep market access leadership experience across NICE, Pfizer, Biogen, Sanofi, and Moderna, where she built assessment-ready value dossiers and evidence packages supporting pricing, reimbursement, and adoption in highly scrutinized markets.
For IMT-358, she is architecting a proactive access strategy designed for rapid institutional uptake — integrating seamlessly into hospital workflows, aligning with payer expectations, and generating the evidence foundation required to support confident, scalable coverage decisions.
Board Of Directors
The Board of Directors provides governance oversight and strategic guidance as IMMEDIATE Therapeutics advances IMT-358 through pivotal development.
Dr. Harry Selker is a physician-scientist and pioneer in emergency cardiovascular care, with decades of experience translating clinical research into practice-changing innovation. He is the founder of IMMEDIATE Therapeutics and served as the principal architect of the NIH-funded IMMEDIATE-1 trial, which established the clinical foundation for IMT-358.
Dr. Selker currently serves as Dean of the Clinical and Translational Science Institute at Tufts University and brings deep expertise in clinical trial design, federal research funding, and systems-level healthcare innovation to the Board.
Atul Deshpande is an experienced biopharmaceutical executive with a track record spanning corporate strategy, fundraising, global operations, and commercialization across large pharmaceutical companies and venture-backed biotechnology firms.
He has previously served on the Board of Directors of Harbour BioMed, supporting the company through its transition from a private biotech to a publicly listed company. Dr. Deshpande brings to the Board experience in capital formation, portfolio strategy, market access, and scaling organizations through late-stage development and public markets.
Dr. Alastair Wood is a distinguished clinician-scientist and internationally recognized authority in clinical pharmacology, drug safety, and regulatory policy. He is Professor Emeritus of Medicine and Pharmacology at Vanderbilt University Medical Center and previously served in senior academic leadership roles including Assistant Vice Chancellor for Clinical Research and Associate Dean for External Affairs.
Dr. Wood served for over a decade as Drug Therapy Editor of The New England Journal of Medicine, where his editorials shaped national discourse on drug safety and regulation. He has chaired and served on multiple FDA advisory committees, including the Cardiovascular and Renal Advisory Committee, and has held board roles at the Critical Path Institute and SmartTots. He brings unparalleled insight into regulatory science, pharmacology, and public-health decision-making to the Board.
Scientific Advisory Board
Chair, Scientific Advisory Board
Dr. James Udelson is a nationally recognized cardiologist and clinical trial leader with extensive experience in cardiovascular drug development, regulatory science, and advanced cardiac imaging.
He serves as Chief of the Division of Cardiology at Tufts Medical Center and is a Professor of Medicine and Radiology at Tufts University School of Medicine. Dr. Udelson has served on multiple FDA advisory committees, including the Cardiovascular and Renal Drugs Advisory Committee and the Medical Imaging Drugs Advisory Panel, and has held senior editorial roles at Circulation and Circulation: Heart Failure.
Dr. Eugene Braunwald is widely regarded as the founder of modern cardiology and a central architect of contemporary cardiovascular medicine.
He is Chairman of the TIMI Study Group, Distinguished Hersey Professor of Medicine at Harvard Medical School, and former Chief of Cardiology and Clinical Director at Brigham and Women’s Hospital. Dr. Braunwald is the editor of Braunwald’s Heart Disease, the definitive textbook in cardiology, and has shaped generations of cardiovascular research, guidelines, and outcomes science.
Dr. Frank Peacock is a leader in emergency cardiovascular medicine and acute care clinical research.
He serves as Vice Chair of Emergency Medicine Research at Baylor College of Medicine and has held leadership roles within the Society of Chest Pain Centers and the Society for Academic Emergency Medicine. Dr. Peacock has led numerous multicenter trials focused on acute coronary syndromes and emergency-department decision-making.
Dr. Michael Levy is a nationally recognized expert in emergency medical systems and pre-hospital care.
He serves as Emergency Medicine Physician at Alaska Regional Hospital, EMS Medical Director for the State of Alaska, and former President of the National Association of EMS Physicians. Dr. Levy has advised on national EMS policy and has served as Chief Medical Advisor for emergency care technologies.
Dr. Darlene Jody is a senior biopharmaceutical executive with extensive experience in global medical affairs and regulatory strategy.
She is CEO of Strategic Biopharma Consulting and previously served as Head of Global Medical Affairs for multiple therapeutic areas at Sanofi, including neurology and oncology. Dr. Jody has also held senior leadership roles at Merck and Bayer-Schering Pharma, overseeing medical, regulatory, and clinical affairs.
Dr. Pamela Douglas is a nationally recognized cardiologist and health-policy leader.
She is Professor of Medicine at Duke University School of Medicine and former President of the American College of Cardiology. Dr. Douglas has served as an advisor to the National Heart, Lung, and Blood Institute and has led major initiatives focused on evidence-based cardiovascular imaging and patient-centered outcomes.
Dr. Edmund Pezalla is a physician executive with deep experience in healthcare strategy, payer engagement, and clinical development.
He is CEO of Enlightenment Bioconsulting and previously served as National Medical Director at Aetna, as well as in senior leadership roles at Pfizer Health Solutions. Dr. Pezalla brings expertise in aligning clinical evidence with payer and system-level decision-making.
Dr. Jai Patel is a senior biopharmaceutical executive with extensive experience in cardiovascular and metabolic disease development and global regulatory strategy.
He currently serves as Chief Medical Officer at Imbria Pharmaceuticals and previously held the role of Chief Medical and Scientific Officer at NephroGenex. Earlier in his career, Dr. Patel was Vice President for Metabolic Pathways and Cardiovascular programs within Global Regulatory Affairs at GlaxoSmithKline and served as Medical Advisor for diabetes, obesity, and biologic products at Bayer (UK).